Robert P. Lisak

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Pharmacy, Neurology, Pharmacotherapy +15

Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture

Martin Raff, Rhona Mirsky, Kay L. Fields et al. · Nature · 1978 · 809 citations

Life Sciences, Biochemistry, Cell Biology +7

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

Alexander Rae‐Grant, Gregory S. Day, Ruth Ann Marrie et al. · Neurology · 2018 · 587 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15